-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Currently, neoadjuvant chemotherapy (NAC) is the only option for patients with locally advanced breast cancer, which can reduce staging and surgical procedures
pCR can be used as a surrogate endpoint for predicting long-term prognosis, including disease-free survival and overall survival, especially in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative subtypes
Although only a minority of patients achieve pCR after NAC, several clinical trials have reported the potential utility of imaging-guided biopsy as a surgical alternative in achieving an imaging complete response (rCR); thus, predicting pCR on MRI becomes more important
Recently, a study published in the journal European Radiology explored the differences in the predictability of MRI for pCR after completion of NAC according to the pathological molecular subtypes of breast cancer patients, and investigated which MRI signs can simulate breast cancer residual and be accurate.
A total of 506 breast cancer patients who underwent MRI after NAC and underwent surgery between January and December 2018 were included in this study
506
The overall pCR rate was 30.
76.
Panel a Initial MR image of a 50-year-old woman with HR-/HER2+ subtype of invasive ductal carcinoma shows a 2.
Original source:
Original source:Jieun Kim, Boo-Kyung Han, Eun Young Ko, et al.
Jieun Kim,Boo-Kyung Han,Eun Young Ko,et al.
Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes .
DOI : 10.
1007/s00330-021-08461-0.
Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes 10.
1007/s00330-021-08461-0.
Leave a message here
